Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015. Physicians provided data for the next five eligible adults who consulted the physician. Patients had a physician-reported history of moderate-to-severe AD. Overall, 284 and 554 adults with physician-perceived mild or moderate AD at the most recent consultation, respectively, were included in the analysis. Patients with moderate AD experienced more flares (p <
.001) and had dry skin, pruritus, and cracking/raw skin day-to-day that were more severe (p <
.0001) and when experiencing a flare (p <
.05) than patients with mild AD. Adults with either mild or moderate AD used a similar number of treatments. Patients with moderate AD reported greater impact on health status, health-related quality of life, and productivity than those with mild AD. Adults with mild-to-moderate AD experienced substantial daily impact from symptoms despite multiple therapies. Unmet needs remain and more can be done to improve disease control in adults with mild-to-moderate AD.